@prefix rdfs:    <http://www.w3.org/2000/01/rdf-schema#> .
@prefix rdf:     <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix pubmed:  <http://bio2rdf.org/pubmed_vocabulary:> .
@prefix skos:    <http://www.w3.org/2008/05/skos#> .
@prefix dcterms:  <http://purl.org/dc/terms/> .

<http://tcga.deri.ie/pubmed/24309609/abstract>
      a       <http://bio2rdf.org/pubmed_vocabulary:ArticleAbstract> ;
      <http://bio2rdf.org/pubmed_vocabulary:abstract_text>
              "Brain tumors are the most common solid tumor diagnosed in childhood that account for significant morbidity and mortality. New therapies are urgently needed; hence, we conducted the first ever prospective open-label phase II trials of the biological response modifier, poly-ICLC, in children with brain tumors. Poly-ICLC is a synthetic double-stranded RNA that has direct antiviral, antineoplastic, and immune adjuvant effects. A total of 47 children representing a variety of brain tumor histopathologic subtypes were treated with poly-ICLC. On the basis of the results of the initial phase II trial, an expanded prospective phase II trial in low-grade glioma (LGG) has been initiated. MRI was used to acquire volume-based measures of tumor response. No dose-limiting toxicities have been observed. In the initial study 3 of 12 subjects with progressive high-grade gliomas (HGGs) responded, and 2 of 4 children with progressive LGG experienced stable disease for 18 to 24 months. In the follow-up LGG phase II study, 2 of 5 LGG patients were stable over 18 months, with 1 stable for 6 months. Overall 5 of 10 LGG patients have responded. On the basis of low toxicity and the promising LGG response, poly-ICLC may be effective for childhood LGG, and the results justify biomarker studies for personalization of poly-ICLC as a single agent or adjuvant." .

<http://tcga.deri.ie/pubmed/24309609/author/8>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Scott R" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "SR" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Vandenberg" .

<http://tcga.deri.ie/pubmed/24309609/author/9>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Tobey J" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "TJ" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Macdonald" .

<http://tcga.deri.ie/pubmed/24309609/Journal>
      a       <http://bio2rdf.org/pubmed_vocabulary:Journal> ;
      <http://bio2rdf.org/pubmed_vocabulary:journal_abbreviation>
              "J. Pediatr. Hematol. Oncol." ;
      <http://bio2rdf.org/pubmed_vocabulary:journal_issue>
              "" ;
      <http://bio2rdf.org/pubmed_vocabulary:journal_title>
              "Journal of pediatric hematology/oncology" ;
      <http://bio2rdf.org/pubmed_vocabulary:journal_volume>
              "" .

<http://tcga.deri.ie/pubmed/24309609/author/10>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Donald L" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "DL" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Durden" .

<http://tcga.deri.ie/pubmed/24309609>
      a       <http://bio2rdf.org/pubmed_vocabulary:PubMedRecord> ;
      rdfs:label "Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors." ;
      <http://bio2rdf.org/pubmed_vocabulary:affiliation>
              "Departments of *Pediatrics §Neuro-oncology #Pathology (Division of Neuropathology), Moores UCSD Cancer Center †Pediatrics ‡Neurosciences/Pediatrics, Rady Children's Hospital, University of California San Diego, La Jolla, CA ∥Oncovir Inc. ¶Children's Oncology Group, Childrens Hospital of Orange County, Orange, CA **Department of Pediatrics, Emory University, AFLAC Cancer Center, Children's Healthcare of Atlanta, Atlanta, GA." ;
      <http://bio2rdf.org/pubmed_vocabulary:author>
              <http://tcga.deri.ie/pubmed/24309609/author/8> , <http://tcga.deri.ie/pubmed/24309609/author/9> , <http://tcga.deri.ie/pubmed/24309609/author/3> , <http://tcga.deri.ie/pubmed/24309609/author/5> , <http://tcga.deri.ie/pubmed/24309609/author/4> , <http://tcga.deri.ie/pubmed/24309609/author/7> , <http://tcga.deri.ie/pubmed/24309609/author/2> , <http://tcga.deri.ie/pubmed/24309609/author/1> , <http://tcga.deri.ie/pubmed/24309609/author/6> , <http://tcga.deri.ie/pubmed/24309609/author/10> ;
      <http://bio2rdf.org/pubmed_vocabulary:journal>
              <http://tcga.deri.ie/pubmed/24309609/Journal> ;
      <http://bio2rdf.org/pubmed_vocabulary:owner>
              "NLM" ;
      <http://bio2rdf.org/pubmed_vocabulary:publication_model>
              "Print-Electronic" ;
      <http://bio2rdf.org/pubmed_vocabulary:publication_type>
              "JOURNAL ARTICLE" ;
      <http://bio2rdf.org/pubmed_vocabulary:status>
              "Publisher" ;
      dcterms:abstract <http://tcga.deri.ie/pubmed/24309609/abstract> ;
      dcterms:identifier "pubmed:24309609" ;
      dcterms:language "ENG" ;
      dcterms:title "Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors." ;
      skos:related <http://tcga.deri.ie/graph/LGG> .

<http://tcga.deri.ie/pubmed/24309609/author/3>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Milan T" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "MT" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Makale" .

<http://tcga.deri.ie/pubmed/24309609/author/5>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Shweta" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "S" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Joshi" .

<http://tcga.deri.ie/pubmed/24309609/author/4>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Mehrzad" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "M" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Milburn" .

<http://tcga.deri.ie/pubmed/24309609/author/2>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "John R" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "JR" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Crawford" .

<http://tcga.deri.ie/pubmed/24309609/author/7>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Beth" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "B" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Hasenauer" .

<http://tcga.deri.ie/pubmed/24309609/author/1>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Lisa L R" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "LL" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Hartman" .

<http://tcga.deri.ie/pubmed/24309609/author/6>
      a       <http://bio2rdf.org/pubmed_vocabulary:Author> ;
      <http://bio2rdf.org/pubmed_vocabulary:fore_name>
              "Andres M" ;
      <http://bio2rdf.org/pubmed_vocabulary:initials>
              "AM" ;
      <http://bio2rdf.org/pubmed_vocabulary:last_name>
              "Salazar" .
